Structure Therapeutics (NASDAQ:GPCR) Sets New 12-Month Low – Should You Sell?

Structure Therapeutics Inc. (NASDAQ:GPCR) hit a new 52-week low on Wednesday . The company traded as low as $13.22 and last traded at $13.91, with a volume of 123479 shares. The stock had previously closed at $14.15.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on GPCR shares. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and issued a $91.00 price target on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus started coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $81.29.

Structure Therapeutics Price Performance

The stock has a market capitalization of $911.75 million, a P/E ratio of -21.49 and a beta of -1.35. The stock has a 50 day moving average price of $21.26 and a 200-day moving average price of $29.37.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Research analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. State Street Corp raised its stake in shares of Structure Therapeutics by 27.0% during the third quarter. State Street Corp now owns 12,295 shares of the company’s stock valued at $540,000 after acquiring an additional 2,611 shares during the last quarter. XTX Topco Ltd increased its holdings in Structure Therapeutics by 100.9% during the 3rd quarter. XTX Topco Ltd now owns 11,938 shares of the company’s stock valued at $524,000 after purchasing an additional 5,997 shares during the period. Nomura Asset Management Co. Ltd. raised its position in Structure Therapeutics by 35.6% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 29,429 shares of the company’s stock valued at $1,292,000 after purchasing an additional 7,719 shares during the last quarter. Barclays PLC lifted its holdings in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock worth $3,562,000 after buying an additional 31,815 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Structure Therapeutics by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock worth $1,985,000 after buying an additional 312 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.